- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02817464
Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle
June 2, 2023 updated by: Teva Branded Pharmaceutical Products R&D, Inc.
A Two-part, Phase 1, Exploratory and Dose-range Finding Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following a Single Subcutaneous Administration of TV-46046 in Women With Ovulatory Cycle
The purpose of this pharmacodynamic and pharmacokinetic study is to identify a dose of TV-46046 (within the range 80 to 300 mg) that is both safe and consistent with contraceptive effect when injected every 6 months.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Teva Investigational Site 001
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Teva Investigational Site 002
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- has regular menstrual cycle (24 to 35 days)
- is at low risk of pregnancy (ie, sterilized, in exclusively same-sex partnership, in monogamous relationship with vasectomized partner, or using non-hormonal IUD)
- is in good general health as determined by a medical history and physical examination
- is not pregnant and does not have desire to become pregnant in the subsequent 36 months
has had a normal mammogram within the last year (for Part 1 only)
- additional criteria apply, please contact the investigator for more information
Exclusion Criteria:
has hypertension:
- systolic blood pressure (BP) ≥160 mm Hg or diastolic BP ≥100 mm Hg
- vascular disease
- has current or history of ischemic heart disease
- has history of stroke
- has history of thromboembolic event
has systemic lupus erythematosus
- positive (or unknown) antiphospholipid antibodies
- severe thrombocytopenia
- has rheumatoid arthritis on immunosuppressive therapy
- has migraine with aura
- has unexplained vaginal bleeding
- has diabetes
- has strong family history of breast cancer (defined as one or more first degree relatives, breast cancer occurring before menopause in three or more family members, regardless of degree of relationship, and any male family member with breast cancer), or current or history of breast cancer, or undiagnosed mass detected by breast exam
- has current or history of cervical cancer
- has severe cirrhosis (decompensated) or liver tumors
- has known significant renal disease
- used Depo-Provera Contraceptive Injection or Depo-subcutaneous Provera 104 (DMPA) products in the past 12 months
used any of the following medications within 1 month prior to enrollment:
- any investigational drug
- prohibited drugs per protocol
- oral contraceptives, contraceptive ring or patch
- levonorgestrel intrauterine system (LNG IUS) or contraceptive implant
- used a combined injectable contraceptive in the past 6 months
- less than 3 months since the end of last pregnancy
- currently lactating
- is using or plans to use prohibited drugs per protocol in the next 18 months
- has known sensitivity to MPA or inactive ingredients
- has a plan to move to another location in the next 24 months
in the opinion of the investigator, potentially at elevated risk of HIV infection (eg, HIV -positive partner, IV drug use by self or by partner)
- additional criteria apply, please contact the investigator for more information
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TV-46046 - 1
|
A single subcutaneous injection in the abdomen of undiluted TV-46046 - 400 mg/mL
|
Experimental: TV-46046 - 2
|
A single subcutaneous injection in the abdomen of saline-diluted TV-46046 - 200 mg/mL
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1: Serum MPA Concentration at Day 7
Time Frame: Day 7
|
Day 7
|
|
Part 1: Serum MPA Concentration at Day 28
Time Frame: Day 28
|
Day 28
|
|
Part 1: Serum MPA Concentration at Day 91
Time Frame: Day 91
|
Day 91
|
|
Part 1: Serum MPA Concentration at Day 182
Time Frame: Day 182
|
Day 182
|
|
Part 1: Serum MPA Concentration at Day 210
Time Frame: Day 210
|
Day 210
|
|
Part 1: Maximum Observed Serum Concentration (Cmax) of MPA
Time Frame: Day 0 up to Week 52
|
Day 0 up to Week 52
|
|
Part 1: Observed Serum Drug Concentration at Day 182 (C182) of MPA
Time Frame: Day 182
|
Day 182
|
|
Part 1: Time to Reach Cmax (Tmax) of MPA
Time Frame: Day 0 up to Week 52
|
Day 0 up to Week 52
|
|
Part 1: Area Under the Serum Drug Concentration by Time Curve From Time 0 to Day 182 (AUC0-182) of MPA
Time Frame: Day 0 up to Day 182
|
Day 0 up to Day 182
|
|
Part 1: Area Under the Serum Drug Concentration by Time Curve From Time 0 to Day 210 (AUC0-210) of MPA
Time Frame: Day 0 up to Day 210
|
Day 0 up to Day 210
|
|
Part 1: Area Under the Serum Drug Concentration by Time Curve From Time 0 to Infinity (AUC0-∞) of MPA
Time Frame: Day 0 up to Week 52
|
Day 0 up to Week 52
|
|
Part 1: Apparent Terminal Half-life (t1/2) of MPA
Time Frame: Day 0 up to Week 52
|
Day 0 up to Week 52
|
|
Part 1: Serum Medroxyprogesterone Acetate (MPA) Concentration at Day 1
Time Frame: Day 1
|
'Overall number of participants analyzed' = participants evaluable for this outcome measure.
|
Day 1
|
Part 2: Time to Ovulation
Time Frame: Day 0 up to Week 78
|
Ovulation was defined as a single elevated serum progesterone ≥4.7 ng/mL.
|
Day 0 up to Week 78
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1: Time to Ovulation
Time Frame: Day 0 up to Week 78
|
Ovulation was defined as a single elevated serum progesterone ≥4.7 ng/mL.
Time to ovulation was computed as the difference in days between detection of the first post-randomization elevated progesterone and the date of treatment initiation.
Median time to ovulation was derived using Kaplan-Meier estimate.
|
Day 0 up to Week 78
|
Part 2: Cmax of MPA
Time Frame: Day 0 up to Week 52
|
Day 0 up to Week 52
|
|
Part 2: Tmax of MPA
Time Frame: Day 0 up to Week 52
|
Day 0 up to Week 52
|
|
Part 2: Observed Serum Drug Concentration at Day 210 (C210) of MPA
Time Frame: Day 0 up to Day 210
|
Day 0 up to Day 210
|
|
Part 2: C182 of MPA
Time Frame: Day 0 up to Day 182
|
Day 0 up to Day 182
|
|
Part 2: AUC0-182 of MPA
Time Frame: Day 0 up to Day 182
|
Day 0 up to Day 182
|
|
Part 2: AUC0-210 of MPA
Time Frame: Day 0 up to Day 210
|
Day 0 up to Day 210
|
|
Part 2: AUC0-∞ of MPA
Time Frame: Day 0 up to Week 52
|
Day 0 up to Week 52
|
|
Part 2: Apparent Terminal Half Life (t1/2) of MPA
Time Frame: Day 0 up to Week 52
|
Day 0 up to Week 52
|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time Frame: Day 0 up to Week 78
|
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Serious adverse events (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition.
AEs were considered TEAEs if onset occurred on or after the first dose date.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
|
Day 0 up to Week 78
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Director: Teva Medical Expert, MD, Teva Branded Pharmaceutical Products R&D, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 26, 2016
Primary Completion (Actual)
December 3, 2018
Study Completion (Actual)
December 3, 2018
Study Registration Dates
First Submitted
June 27, 2016
First Submitted That Met QC Criteria
June 27, 2016
First Posted (Estimated)
June 29, 2016
Study Record Updates
Last Update Posted (Actual)
February 12, 2024
Last Update Submitted That Met QC Criteria
June 2, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- TV46046-WH-10075
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy
-
Far Eastern Memorial HospitalCompletedCornual PregnancyTaiwan
-
Peking Union Medical College HospitalPeking Union Medical CollegeUnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk FactorChina
-
Ufuk UniversityNot yet recruitingPregnancy Complications | Pregnancy Loss | Pregnancy Preterm
-
Hadassah Medical OrganizationCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompletedProlonged PregnancyFrance
-
University Hospital, ToursCompleted
-
Technische Universität DresdenWithdrawnPregnancy Trimester, Second | Pregnancy Trimester, First | Pregnancy Trimester, ThirdGermany
-
Universitair Ziekenhuis BrusselMerck Serono International SAUnknownPregnancy | Pregnancy LossBelgium
-
Turku University HospitalUniversity of TurkuCompleted
-
Hopital Antoine BeclereUnknown
Clinical Trials on TV-46046 - 400 mg/mL
-
Ixchelsis LimitedCompleted
-
Richever Enterprise Co., Ltd.UnknownGalactose Single Point (GSP), Residual Liver Function
-
Teva Branded Pharmaceutical Products R&D, Inc.FHI 360CompletedContraceptionDominican Republic
-
Maimónides Biomedical Research Institute of CórdobaConsejería de Salud y Familias - Junta de Andalucía; Red Andaluza de Ensayos...Completed
-
Dr. Reddy's Laboratories LimitedXenoPort, Inc.Completed
-
Chengdu PLA General HospitalUnknown
-
AmtixBio Co., Ltd.Novotech (Australia) Pty LimitedCompleted
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Germany
-
Dr. Reddy's Laboratories LimitedCompleted
-
National Defense Medical Center, TaiwanTri-Service General Hospital; Cardinal Tien HospitalCompletedGalactose Single Point (GSP), Residual Liver Function